http://www.supergen.com/?main=home

Gavin Choy, PharmD – VP, Clinical Operations
David Bearss, MD – VP, Chief Scientist  

Presentation on:

• MP470 (Multi-TKI/ Rad51 Suppressor)
• MP529 (Aurora Inhibitor)
• S110 (DNMT Inhibitor)

---

http://www.exelixis.com

Dana T Aftab, PhD - VP, Translational Research
Art DeCillis, MD - VP, Clinical Research

Presentation on:

• "Targeting kinase signaling pathways with small molecules for the treatment of cancer"

---

http://www.thresholdpharm.com/

John Curd, MD - President, Chief Medical Officer

Presentation on:

• Glufosfamide – ifosfamide alkylator/glucose conjugate
• Hypoxia-Activated Prodrug (Th-302)
• 2-Deoxyglucose

---

http://www.nereuspharm.com

Matt Spear, MD - Chief Medical Officer, Vice President
Michael Paladino, MD - Chief Technical Officer

Presentation on:

• NPI-2538 – Vascular Disrupting Agent
• NPI-0052 – Proteasome Inhibitor

---

http://www.merck.com

Stephen Friend, MD - Executive Vice President, Oncology

Presentation on:

• "Can Pre-clinical Work Impact Clinical Trials?"

---

http://www.pharmacyclics.com

Sriram Balasubramanian, PhD - Director Translational Research
Markus Renschler, MD, SVP, Oncology Clinical Development

Presentation on:

• PCI-24781 – HDAC inhibitor
• PCI-27483 – Factor VIIa inhibitor
• PCI-32765 – Tyrosine kinase inhibitor

---

http://www.mgipharma.com

Jie Zhang, PhD - Principal Scientist II
Krystyna Wozniak, PhD - Director, Animal Pharmacology
Beth Zaharoff - Senior Medical Science Liaison
Mary Osbakken - President, Osbakken Consulting –Medical Monitor for MGI for PARP Program
Anthony Kiorpes, PhD  - Director of Toxicology

Presentation on: 

• PARP Inhibitor Program

---

http://www.pharma.bayer.com/en/home.html

Jeffrey S. Humphrey, MD, Vice President, US Medical Sciences, Oncology
Karl-Heinz Thierauch, PhD, Therapeutic Research Oncology, Bayer-Schering

Presentation on:

Clinical:

• Nexavar® (sorafenib): multi-kinase inhibitor for the treatment of advanced renal cell carcinoma
• Leukine® (sargramostim): GM-CSF (granulocyte-macrophage colony-stimulating factor) in AML
• Campath® (alemtuzumab): for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy.
• Fludara® (fludarabine phosphate): FLUDARA® (fludarabine phosphate) antineoplastic agent for refractory B-CLL
• Zevaline® (Ibritumomab Tiuxetan): [90Y]-radiolabelled Zevalin: for adult patients with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL).

Pre-clinical:

• Tocosol (paclitaxel emulsion): under development for treatment of women with metastatic breast cancer
• Sagopilone (ZK-Epo): in phase 2 development
• Other pipeline compounds currently in clinical development

---

http://www.mgipharma.com

Michael Cullen Jr, MD - Vice President, Clinical Affairs/ Chief Medical Officer
Beth Zaharoff - Senior Medical Science Liaison

Presentation on:

• Dacogen - AML
• Amolimogene – for cervical dysplasia
• Irofulven – various solid tumors
• ZYC300 - for solid tumors
• GCPII - for chemotherapy induced neuropathy
• PARP inhibitors

---

http://www.boehringer-ingelheim.com/corporate/home/home.asp

Wolfgang Rettich, MD - Senior Vice President Research
Andree Amelsberg, MD, MBA - Executive Director  Oncology
Gerd Stehle, MD - Therapeutic Head Oncology

Presentation on:

• Overview of Oncology Drug Discovery Research and Clinical Research at Boehringer Ingelheim
• BIBW 2992 - Dual, Irreversible EGFR/HER2 Inhibitor
• BIBF 1120 - Triple Angiokinase Inhibitor
• BI 2536 - First-In-Class Plk1 inhibitor

---

http://www.osip.com/

Phil Rutledge, MA, MBA - Director, Medical Sciences Liaison
John Haley, PhD - Senior Research Director, Translational Research

Presentation on:

• OSI-906 – IGF-1R Inhibitor
• Tarceva
• Torc1/ Torc2 Inhibitor

---

http://www.cyclacel.com

Judy Chiao, MD - VP, Clinical Development and Regulatory Affairs
Simon Green, PhD - Team Leader

Presentation on:

• Seliciclib - oral CDK inhibitor
• Sapacitabine -oral nucleoside analog
• CYC116 - oral aurora kinase inhibitor

---

http://www.biogenidec.com/

David R Parkinson, MD - Senior VP, Oncology Research and Development

Presentation on:

• Rituximab
• Galiximab - Anti-CD80
• Lumiliximab - Anti-CD23
• Volociximab - Anti-alpha5 beta 1
• Hsp90 inhibitors - BIIB021 and BIIB028
• Anti-Crypto immunoconjugate

---

http://www.roche.com/home.html

David Heimbrook, PhD - VP Nutley Oncology Research and Global Therapy Area Head Oncology
Kapil Dhingra, MD - VP Group Leader Oncology
Catherine Wheeler, MD - Therapeutic Expert for Medical Science - Oncology

Presentation on:

• Brief Overview Genentech/Roche Relationship
• Late Stage Compounds (Avastin, Herceptin, Rituxan, Xeloda, Tarceva)
• Early Stage Compounds:
  • Omnitarg, Epothilones, CDK Inhibitor, MAI (Mitosis-Angiogenesis Inhibitor)
  • Anti-IGFR-1 Antibody, Selective mutant b-raf Inhibitor
  • Glyco-engineered anti-CD20 Antibody
  • MDM2-p53 interaction inhibitor

---

http://www.protoxtherapeutics.com/

Fahar Merchant, MD - President and CEO

Presentation on:

• PRX302 – Engineered version of proaerolysin, a pore-forming protein secreted by the bacteria Aeromonas hydrophilia – localized, recurrent prostate cancer, BPH
• PRX321 – toxin fusion protein that has been evaluated for the treatment of glioma and in patients with peripheral solid tumors that over-express IL-4 receptors, such as kidney and lung carcinoma

---

http://www.tigrispharma.com/

Binh Nguyen, MD - Vice President of Clinical Development and Operations

Presentation on:

• Immunomodulator A007 for cervical dysplasia (currently in phase 2),
• AFP-464 - an  aminoflavone pro-drug (currently in phase 1  -potential indications renal and breast )
• Two pre-clinical drugs: The Anti-VEGF/PDGF drug GFB204 and The GGTI inhibitor GGTI2418 (solid tumors)

---

 

 

---

 

http://www.reatapharma.com/index.asp

Colin J Meyer, MD, MBA - Director of Product Development
Paul Foster, MD - Chief Medical Officer, VP Clinical Development and Regulatory Affairs
Leslie Lescale-Matys, MD - Director of Clinical Programs

Presentation on:

• RTA 402 - NF kappa B and STAT3 Inhibitor
• RTA 744 - Novel Anthracycline derivative (crosses blood-brain barrier)
• Update on preclinical efforts
• p53 protein misfolding array

---

http://www.attenuon.com/

Andrew P Mazar, PhD, Chief Scientific Offocer, Senior Vice President Research and Development
Josh L Distler - Chief Operations Officer, Senior Vice President

Presentation on:

• ATN-658, Monoclonal antibody specific for the D2D3 domain of uPAR
• ATN-224, SOD-1 Inhibitor

---

http://www.progen.com.au/

Anand Gautam, PhD - Vice President, Research and Development

Presentation on:

• PI-88 – Anti-angiogenic compound in Phase II for melanoma, prostate, liver and lung cancer
• PI-166 – for unresectable hepatocellular carcinoma

---

http://ipi.com/

Julian Adams, PhD - President of Research and Development and Chief Scientific Officer
David Grayzel, MD - Vice President, Clinical and Medical Affairs

Presentation on:

• IPI-504 - Hsp 90 Inihibitor

---

http://www.astex-therapeutics.com/home.php

 Murray Yule, MD - Company Physician 

Presentation on:

•  AT-7519 - potent cell cycle inhibitor in early clinical development for the treatment of advanced solid tumors and hematologic cancer. The drug targets key cyclin-dependent kinases (CDKs), resulting in tumor shrinkage.
• AT-9311 - Cyclin-Dependent Kinase Inhibitor

---

http://www.amgen.com

C Glenn Begley, MBBS, PhD - VP, Hematology & Oncology Research
Jan Pinkas, PhD - Senior Scientist, Oncology Research
Douglas Saffran, PhD - Principal Scientist, Oncology Research

Products Presented:

• Amgen 479 - Anti-CD221 (IFG1-R) Monoclonal Antibody
• Amgen 706 - Oral, multi-kinase inhibitor, anti-angiogenic
• Denosumab - Anti-RANKL Monoclonal Antibody

---

http://www.Entremed.com

Mark R Bray, M.Sc, PhD – Senior Director, Preclinical Sciences
Carolyn Sidor, MD, MBA – Vice President, Chief Medical Officer
Theresa LaValle, PhD – Senior Director, Cell Biology

Presentation on:

• 2-methoxyestradiol (now in several small Phase 2 studies)
• ENMD-1198 - an analog of 2-methoxyestradiol - now in Phase 1 
• MKC-1, a cell cycle regulator licensed from Roche now in two Phase 2 studies
• ENMD981693, an AK/RTK inhibitor

---

http://www.celgene.com

Bob Delap, MD, PhD - Vice President Global Medical Research
Peter Schafer, MD - Director of Biology

Presentation on:

• IMIDS (Immunomodulatory Drugs):
  • Panmilomide (formerly Actimid, CC-4047)
  • Revlimid (Lenalidomide)
• SelCIDS (Selective Cytokine Inhibitory Drugs):
  • JNK-2 Inhibitors

---

http://www.ptcbio.com

Langdon Miller, MD – Chief Medical Officer
Samit Hirawat, MD – Senior Director, Clinical Development 

Presentation on:

• PTC-124 - novel, orally administered small-molecule compound that targets a particular genetic alteration known as a nonsense mutation
• PTC-299 - novel, orally administered small-molecule compound designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors

---